A clinical case of asymptomatic pancreatic hyperenzymemia on the background of taking a Glucagon-like peptide-1 analogue (GLP-1)





asymptomatic pancreatic hyperenzymemia, glucagon-like peptide-1, type 2 diabetes


 According to current statistics, the incidence of type 2 diabetes has increased significantly over the past few years. The number of drugs prescribed to correct carbohydrate metabolism is also increasing, and new groups of hypoglycemic drugs are appearing. This prompts a more detailed study and analysis of the possible side effects of the prescribed therapy. One of the modern groups of medications f  or treating type 2 diabetes are analogues of glucagon-like peptide-1 receptor agonists, which, in addition to correcting carbohydrate metabolism, have a beneficial effect on the risk of developing cardiovascular events. Despite this, there is evidence that their use may be associated with the development of undesirable adverse effects from the pancreas, particularly acute pancreatitis, pancreatopathy, or asymptomatic hyperenzymemia. The aim of our work was the analysis of a clinical case of an asymptomatic increase in the level of pancreatic enzymes (Gullo's syndrome) in a patient with type 2 diabetes, who used a glucagon-like peptide-1 receptor analogue for treatment according to the usual scheme (dulaglutide 0.75 mg subcutaneously once a week during 2 years). As a result, the patient developed a side effect that could be related to taking this medicine. This did not lead to the withdrawal of the drug but required a more thorough examination of the patient and regular further screening for the timely detection of the development of possible organic pathology of the pancreas in the future. So, after analyzing this clinical case, it is possible to see the possibility of developing asymptomatic pancreatic hyperenzymopathy during the treatment of type 2 diabetes mellitus with glucagon-like peptide-1 receptor agonist analogues, which should be taken into account when determining the treatment tactics.


Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, et al. Glucagon-like peptide 1 (GLP-1) [Internet]. Mol Metab. 2019 Dec [cited 2023 Mar 24];30:72-130. doi: https://doi.org/10.1016/j.molmet.2019.09.010

Kuhre RE, Deacon CF, Holst JJ, Petersen N. What Is an L-Cell and How Do We Study the Secretory Mecha-nisms of the L-Cell? [Internet]. Frontiers in Endocrinology. 2021 [cited 2023 Mar 24];12. doi: https://doi.org/10.3389/fendo.2021.694284

Gilbert MP, Pratley RE. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials [Internet]. Front Endocrinol (Lausanne). 2020 Apr 3 [cited 2023 Mar 24];11:178. doi: https://doi.org/10.3389/fendo.2020.00178

Costa A, Ai M, Nunn N, Culotta I, Hunter J, Boudjadja MB, et al. Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation [Internet]. Molecular Metabolism. 2022 Jan [cited 2023 Mar 24];55:101407. doi: https://doi.org/10.1016/j.molmet.2021.101407

Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art [Internet]. Molecular Metabolism. 2021 Apr [cited 2023 Mar 24];46. doi: https://doi.org/10.1016/j.molmet.2020.101102

Scheen AJ. Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes [Internet]. Rev Med Liege. 2016 Mar [cited 2023 Mar 24];71(3):154-60. PMID: 27311248

Amaro A, Sugimoto D, Wharton S. Efficacy and safety of semaglutide for weight management: evidence from the STEP program [Internet]. Postgrad Med. 2022 Jan [cited 2023 Mar 24];134(Sup 1):5-17. doi: https://doi.org/10.1080/00325481.2022.2147326

Cabral Lopes A, Roque F, Lourenço O, Herdeiro MT, Morgado M. Gastrointestinal disorders potentially associated with Semaglutide: an analysis from the Eudravigilance Database [Internet]. Expert Opinion on Drug Safety. 2023 Feb [cited 2023 Mar 24]2;1-7. doi: https://doi.org/10.1080/14740338.2023.2172159

Mehta P, Reddivari A. A Case Report of Benign Pancreatic Hyperenzymemia (Gullo’s Syndrome) [Internet]. Cureus. 2020 May [cited 2023 Mar 24];12(5):e8143. doi: https://doi.org/10.7759/cureus.8143

Warshaw AL, Lee KH. Macroamylasemia and other chronic nonspecific hyperamylasemias: chemical oddities or clinical entities? [Internet]. Am J Surg. 1978 Apr[cited 2023 Mar 24];135(4):488-93. doi: https://doi.org/10.1016/0002-9610(78)90025-9

Gullo L. Chronic nonpathological hyperamy-lasemia of pancreatic origin. [Internet]. Gastroenterology. 1996 Jun [cited 2023 Mar 24];110(6):1905-8. doi: https://doi.org/10.1053/gast.1996.v110.pm8964417

Gullo L. Benign pancreatic hyperenzymemia [Internet]. Dig Liver Dis. 2007 Jul [cited 2023 Mar 24];39(7):698-702. doi: https://doi.org/10.1016/j.dld.2007.03.005

Rycyk A, Furtak P, Mądro A, Kasztelan-Szczerbińska B, Cichoż-Lach H. Gullo’s syndrome – what do we know? [Internet]. Gastroenterology Rev. 2021 [cited 2023 Mar 24];16(3):181-3. doi: https://doi.org/10.5114/pg.2020.101133

Huberhritz NB, Belyaeva NV, Lukashevich HM, Mozhyna TL. [Secrets, riddles, and mysteries of macro-amylasemia]. Visnyk klubu pankreatolohiv. 2020;2:12-22. Russian. doi: https://doi.org/10.33149/vkp.2020.01.02




How to Cite

Sanina N, Hondulenko N, Panina S, Shulha V. A clinical case of asymptomatic pancreatic hyperenzymemia on the background of taking a Glucagon-like peptide-1 analogue (GLP-1). Med. perspekt. [Internet]. 2023Sep.29 [cited 2024Mar.3];28(3):213-7. Available from: https://journals.uran.ua/index.php/2307-0404/article/view/289229